Major Force in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market 2025: Rising Cancer Rates Drive Growth In Cell And Gene Therapy CDMO Market

How Will the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Grow, and What Is the Projected Market Size?
The market size for contract development and manufacturing organizations (CDMO) in the cell and gene therapy industry has experienced a rapid surge in recent times. It's projected to rise from $5.41 billion in 2024 to $6.94 billion in 2025, displaying a compound annual growth rate (CAGR) of 28.2%. The historical growth period's expansion can be accredited to factors such as enhanced technological advancements, accommodating regulatory environments, increased financial input, a high rate of genetic conditions, and a rise in strategic collaborations.

The market for contract development and manufacturing organization (CDMO) involved in cell and gene therapy is projected to undergo colossal growth in the coming years. The market will increase to a size of $18.54 billion by 2029, with a compound annual growth rate (CAGR) of 27.8%. The projected surge during the forecast period is credited to the expansion of therapeutic applications, evolved regulatory environment, heightened investments, innovative technology, and international collaborations. Future trends for the forecast period encompass a surge in demand for personalized treatment, rise in automation and digitization, widening of manufacturing capabilities, emergence of unique delivery systems, and a heightened emphasis on sustainability and environmental accountability.

What Is Stimulating Growth in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
The rise in cancer instances is predicted to stimulate the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market in the future. Cancer is a collection of diseases distinguished by rampant growth and distribution of anomalous cells in the body. The surge in cancer instances is attributed to factors such as aging populations, lifestyle shifts, environmental risks, and enhanced detection techniques. The cell and gene therapy contract development and manufacturing organization (CDMO) contributes to reducing cancer prevalence by creating and producing forward-thinking, targeted therapies that augment efficacy and patient results. For example, October 2022 data from Macmillan Cancer Support, a UK-based charity, suggest that the anticipated number of UK residents living with cancer is set to rise from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalation in cancer instances is fuelling the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Who Are the Major Industry Players Fueling Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Expansion?
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

Which Key Developments Are Influencing the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
Top companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are concentrating their efforts on broadening their range of offerings with sophisticated solutions like PluriMatrix technology. This innovation is designed to improve the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology, a proprietary system designed specifically for large-scale cell-based product manufacturing, enables cells to expand in three dimensions on an industrial scale. The automated, fully controlled, and validated process guarantees high production volumes and consistent quality. In January 2024, for example, Pluri, a biotech firm from Israel, unveiled PluriCDMO, a new business unit that provides cell therapy manufacturing services as a CDMO. This new unit encompasses a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri's new division offers comprehensive services ranging from early preclinical stages to late-stage clinical trials and market entry. These services include process and analytical development, scale-up, validation, logistics, automation, and regulatory-compliant comparability studies, as specified in a company press statement. It employs the company's proprietary PluriMatrix technology to provide advanced cell therapy manufacturing services.

How Is the Segmentation of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Defined?
The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented -

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

What Is the Leading Region in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report?

- Market Size Analysis: Analyze the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.